News | Thrombectomy Devices | May 21, 2018

Medtronic MindFrame Capture LP Revascularization Device Recalled

FDA warns of risk of delivery wire breaking or separating during use, which could cause device to be left in patient’s bloodstream

Medtronic MindFrame Capture LP Revascularization Device Recalled.

May 21, 2018 — Medtronic and the U.S. Food and Drug Administration (FDA) announced a Class I Urgent Medical Device Recall of the MindFrame Capture LP revascularization device on account of a risk of the delivery wire breaking or separating during use. The FDA said the clot retriever could be left inside the patient’s bloodstream, and this or the attempts made to retrieve the device, can lead to further complications; these complications include bleeding, additional blockage of blood vessels, more severe stroke symptoms or death.

On April 4, 2018, Medtronic followed up with their customers with another Urgent Medical Device Recall notice regarding patient management. The notice recommended healthcare providers to:

  • Review the notification and distribute the information to all appropriate personnel;
  • Follow up with the patient closely;
  • Consider antiplatelet therapy;
  • Consider repeating imaging on the patient; and
  • Complete and return the acknowledgement and receipt form to Medtronic.

The MindFrame Capture LP revascularization device is intended to restore blood flow or remove blood clots within a blood vessel in the brain during an acute ischemic stroke in patients who are ineligible for or fail intravenous tissue plasminogen activator (IV t-PA) therapy.

The total number of devices recalled in the U.S. has reached 529, according to the FDA. Product lot numbers affected by the recall are as follows: 300010, 300011, 300012, 300013, 300014, 300015, 300016, 300017 and 300018. Affected devices were manufactured between Feb. 3, 2016, and Jan. 14, 2018; they were distributed between March 18, 2016 and Jan. 17, 2018.

Customers with questions may contact Medtronic Quality Assurance by email at [email protected] or by phone at 1(800) 633-8766.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report online:
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

For more information:,

Related Content

National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Overlay Init